Method of producing personalized biomimetic drug-eluting coronary stents by 3D-printing

Patent metadata

Field	Value
Publication number	US-9943627-B2
Application number	US-201514743782-A
Country	US
Kind code	B2
Filing date	Jun 18, 2015
Priority date	Mar 3, 2015
Publication date	Apr 17, 2018
Grant date	Apr 17, 2018

Abstract

A method for using 3D printing technology produces personalized biomimetic drug-eluting coronary stent and the product thereof. The process of manufacturing stent, based on coronary angiography imaging data, measures the diameter of diseased coronary and conducts 3D reconstruction. A personalized stent for each patient according to diameter, length, and morphological characteristics of target vessel that suited to the lesion is produced. The coronary stent is formed from biodegradable poly-L-lactic acid (PLLA) or other materials. The stent is modeled by 3D printing and then coated with polymers carrying antiproliferative drug to reduce restenosis (the polymers is a mixture of antiproliferative drug and PDLLA at a ratio of 1:1). The biomimetic drug-eluting coronary stent produced by 3D printing technology is personalized stent for each patient according to different characteristics of diseased coronary, reduces the incidence of vascular injury, thrombosis, dissection and other complications caused by stent and vessel diameter mismatch.

First claim

The invention claimed is:

1. A method of producing a personalized biomimetic drug-eluting coronary stents by 3D-printing, comprising the steps of:
(1) obtaining morphological data of a diseased coronary artery by using Quantified Coronary Angiography (QCA); designing an overall shape of a coronary stent in an expanded state, and determining topological structure of the coronary stent, thereby generating a 3D model of the coronary stent; processing a 3D model by using a layering software, so as to generate layer data for a 3D printing platform;
wherein, the coronary stent has an overall conical shape in the expanded state, a diameter of a proximal end of the coronary stent is larger than a diameter of a distal end of the coronary stent; or, the coronary stent has an overall irregular shape in the expanded state;
(2) performing 3D printing by means of Melted Extrusion Modeling (MEM), wherein, biodegradable material is extruded under a controlled condition through a friction drive nozzle, a screw nozzle, a pneumatic nozzle or a straight pointed nozzle, and the extruded material is manipulated by a control software of the 3D printing platform to form the coronary stent;
or,
performing 3D printing by means of Selective Laser Melting/Sintering (SLM/SLS), wherein, powder of biodegradable material is prepared and laid on a support plate of the 3D printing platform, and the powder is selectively scanned with controlled laser beam in a layer-by-layer manner according to said layer data;
(3) coating the coronary stent with anti-proliferative drug, so as to produce the biomimetic drug-eluting coronary stent.

2. The method of claim 1 , wherein,
when the 3D printing is performed by means of Melted Extrusion Modeling, the extruded material has a diameter of 50-300 μm;
or,
when the 3D printing is performed by means of Selective Laser Melting/Sintering, the controlled laser beam has a feature size of 50-300 μm.

3. The method of claim 1 , wherein, the biodegradable material is PLLA (poly-L-lactic acid).

4. The method of claim 2 , wherein, the biodegradable material is PLLA (poly-L-lactic acid).

Assignees

• Zhou Yujie
• Sun Wei
• Ma Qian
• Zhang Lei

Inventors

• Zhou Yujie
• Sun Wei
• Ma Qian
• Zhang Lei

Classifications

• A61B2090/061

  for measuring dimensions, e.g. length · CPC title

• B29K2067/046

  PLA, i.e. polylactic acid or polylactide · CPC title

• A61B90/06

  Measuring instruments not otherwise provided for · CPC title

• A61F2210/0004

  bioabsorbable · CPC title

• A61L31/16 Primary

  Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} · CPC title